Navigating the Future: Artificial Intelligence (AI) In Biopharmaceuticals Market Trends and Forecast Insights, 2025 Edition

"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Artificial Intelligence (AI) In Biopharmaceuticals Market Size Growth Forecast: What to Expect by 2025?
The market size of artificial intelligence (AI) in the biopharmaceuticals sector has seen an incredible rise in recent years. The predictions indicate an increase from $1.59 billion in 2024 to $2.1 billion in 2025, featuring a compound annual growth rate (CAGR) of 32.2%. The observed growth during the historical span can be credited to improvements in computation power, the surge in biomedical data, the model of precision medicine, and support and guidance from regulatory authorities.

How Will the Artificial Intelligence (AI) In Biopharmaceuticals Market Size Evolve and Grow by 2029?
The biopharmaceutical sector's artificial intelligence (AI) market is predicted to experience considerable expansion in the coming years. It is forecasted to reach a valuation of $6.58 billion by 2029, growing at a compound annual growth rate (CAGR) of 33.0%. Drivers of growth for the predicted period include advances in computational biology, multi-modal data integration, the intersection of AI and life sciences, regulatory support and structures, as well as ethical and unbiased AI principles. Key trends for the future period include the assimilation of multi-omics data, AI-guided drug creation and discovery, understandable AI and regulatory approval, technological progress, regulatory advancements, and burgeoning opportunities.

View the full report here:
https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-biopharmaceuticals-global-market-report

What Drivers Are Propelling the Growth of Artificial Intelligence (AI) In Biopharmaceuticals Market Forward?
The consistent rise in chronic diseases prevalence is projected to stimulate the expansion of the artificial intelligence (AI) application in the biopharmaceuticals market. Chronic diseases are typically long-lasting and slowly progressing conditions that can linger for many years, even a lifetime. These diseases can emerge due to various factors including lifestyle choices, an aging demographic, genetic factors, and environmental causes. AI is finding more usage in managing chronic diseases in the biopharmaceutical sector as it facilitates the analysis of large amounts of diverse data, identification of patterns, and customization of treatment strategies. For example, the Department of Health and Human Services, a government department in the US, reported in November 2023 that there was an 11 percent surge in newly reported chronic hepatitis B cases in 2022, as compared to 2021. Consequently, the consistent rise in chronic disease prevalence prompts the expansion of artificial intelligence (AI) in the biopharmaceutical market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14251&type=smp

What Long-Term Trends Will Define the Future of the Artificial Intelligence (AI) In Biopharmaceuticals Market?
Major corporations in the biopharmaceutical field using artificial intelligence (AI) are striving to create innovative breakthroughs. These include an AI-powered target and lead identification suite that hastens drug discovery and precision medicine, transforming corporations in the life sciences. These innovative strategies extend to the development of new drugs and the customizing of treatments for individual patients. For example, in May 2023, Google LLC, a US-based cloud computing service provider, unveiled two new AI-powered tools named target and lead identification suite. These tools assist researchers in predicting and decoding protein structures, an essential aspect of drug development. Furthermore, this suite is crucial for precision medicine as it enables researchers to ingest, store, analyze, and share extensive genomic data. These tools also aim to streamline the process of drug discovery, reduce expenses, and expedite the introduction of new treatments to the market. By facilitating efficient data management, precise prediction of protein structures, and sophisticated genomic analysis, these tools aspire to renovate drug development procedures and enhance patient outcomes.

What Are the Key Segments in the Artificial Intelligence (AI) In Biopharmaceuticals Market?
The artificial intelligence (ai) in biopharmaceuticals market covered in this report is segmented -

1) By Offering: Hardware, Software, Services
2) By Deployment: Cloud, On-Premises
3) By Technology: Machine Learning, Natural Language Processing, Deep Learning, Other Technologies
4) By Application: Business Process And Supply Chain, Drug Discovery, Medical Imaging And Diagnostics, Precision Medicine
5) By End-Users: Manufacturers, Contract Research Organizations, Academic And Government Research Institutes

Subsegments:
1) By Hardware: High-Performance Computing Systems, AI-Enabled Laboratory Equipment, Data Storage Solutions
2) By Software: Drug Discovery Platforms, Clinical Trial Management Software, Predictive Analytics Tools, Natural Language Processing Solutions
3) By Services: Consulting Services, Implementation And Integration Services, Data Management And Analytics Services, Training And Support Services

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=14251&type=smp

Who Are the Key Players Shaping the Artificial Intelligence (AI) In Biopharmaceuticals Market's Competitive Landscape?
Major companies operating in the artificial intelligence (AI) in biopharmaceuticals market are Apple Inc., Google LLC, Microsoft Corporation, Tencent Holdings Limited, Amazon Web Services Inc., International Business Machines Corporation, Exscientia Limited, NVIDIA Corporation, Amgen Inc., DeepMind Technologies Limited, Schrödinger Inc., XtalPi Inc., ConcertAI Inc., Insilico Medicine Inc., Recursion Pharmaceuticals, BenevolentAI, BioXcel Therapeutics, Atomwise Inc., BioAge Labs Inc., GNS Healthcare, Berg Health, Deep 6 AI Inc., Cloud Pharmaceuticals Inc., Numerate Inc., AI Therapeutics, Envisagenics, twoXAR Inc., Cyclica Inc.

What Geographic Markets Are Powering Growth in the Artificial Intelligence (AI) In Biopharmaceuticals Market?
North America was the largest region in the artificial intelligence (AI) in biopharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) in biopharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14251

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

#Reach Out to Us#

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

This release was published on openPR.